Fundraising Fox
Arcturus Therapeutics
NASDAQ: ARCTSan Diego, US · Founded 2013 · Incorporated in Delaware · 1 known investors
Find your way into Arcturus Therapeutics
Sign up to see every warm intro you have to Arcturus Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Arcturus Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Arcturus develops messenger RNA therapeutics and vaccines targeting rare genetic diseases and infectious pathogens, including a self-amplifying mRNA COVID-19 vaccine approved in Japan and Europe, along with clinical-stage candidates for cystic fibrosis and ornithine transcarbamylase deficiency.
Founders & leadership
Arcturus Therapeutics was founded in 2013 by Pad Chivukula and Padmanabh Chivukula.
PC
Pad ChivukulaCo-founder
PC
Padmanabh ChivukulaCo-founder
JE
Joseph E. PaynePresident and Chief Executive Officer
Board
SC
Stuart CollinsonBoard director
DS
David ShapiroBoard director
CW
Craig WillettBoard director
OT
Orli ToriBoard director
DG
Daniel GeffkenBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$73.7M disclosed across 2 rounds · 2014–2017
▶$67.8MraisedJan 2018 · 82 investors · BiotechnologyRule 506(b)
▶$67.8MraisedJan 2018 · 82 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David ShapiroDirector
- Stuart CollinsonDirector
- Pad ChivukulaExecutive Officer, Director
- Craig WillettDirector
- Orli ToriDirector
- Joseph E PayneExecutive Officer, Director
- Daniel GeffkenDirector
- Offering amount
- $67.8M
- Amount sold
- $67.8M
- Sales commissions
- $950K
- First sale
- Nov 2017
- Incorporated
- Other, Israel
- Federal exemptions
- 06b
▶$5.9MraisedOct 2015 · 43 investors · BiotechnologyRule 506(b)
▶$5.9MraisedOct 2015 · 43 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Craig WillettDirector
- Joseph Edward PayneExecutive Officer, Director
- Padmanabh ChivukulaExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $5.9M
- First sale
- Oct 2014
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Arcturus Therapeutics do?
- Arcturus develops messenger RNA therapeutics and vaccines targeting rare genetic diseases and infectious pathogens, including a self-amplifying mRNA COVID-19 vaccine approved in Japan and Europe, along with clinical-stage candidates for cystic fibrosis and ornithine transcarbamylase deficiency.
- Who founded Arcturus Therapeutics?
- Arcturus Therapeutics was founded by Pad Chivukula, Padmanabh Chivukula in 2013.
- Who are Arcturus Therapeutics's investors?
- Arcturus Therapeutics's investors include Khosla Ventures.
- How much funding has Arcturus Therapeutics raised?
- Arcturus Therapeutics has disclosed $73.7M raised across 2 rounds.
- Where is Arcturus Therapeutics headquartered?
- Arcturus Therapeutics is headquartered in San Diego, US.